title: Prevention of tobacco carcinogen-induced lung cancer in female mice using antiestrogens.
abstract: Increasing evidence shows that estrogens are involved in lung cancer proliferation and progression, and most human lung tumors express estrogen receptor β (ERβ) as well as aromatase. To determine if the aromatase inhibitor anastrozole prevents development of lung tumors induced by a tobacco carcinogen, alone or in combination with the ER antagonist fulvestrant, ovariectomized female mice received treatments with the tobacco carcinogen 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone (NNK) along with daily supplements of androstenedione, the substrate for aromatase. Placebo, anastrozole and/or fulvestrant were administered in both an initiation and a promotion protocol of lung tumorigenesis. The combination of fulvestrant and anastrozole given during NNK exposure resulted in significantly fewer NNK-induced lung tumors (mean = 0.5) compared with placebo (mean = 4.6, P < 0.001), fulvestrant alone (mean = 3.4, P < 0.001) or anastrozole alone (mean = 2.8, P = 0.002). A significantly lower Ki67 cell proliferation index was also observed compared with single agent and control treatment groups. Beginning antiestrogen treatment after NNK exposure, when preneoplastic lesions had already formed, also yielded maximum antitumor effects with the combination. Aromatase expression was found mainly in macrophages infiltrating preneoplastic and tumorous areas of the lungs, whereas ERβ was found in both macrophages and tumor cells. Antiestrogens, especially in combination, effectively inhibited tobacco carcinogen-induced murine lung tumorigenesis and may have application for lung cancer prevention. An important source of estrogen synthesis may be inflammatory cells that infiltrate the lungs in response to carcinogens, beginning early in the carcinogenesis process. ERβ expressed by inflammatory and neoplastic epithelial cells in the lung may signal in response to local estrogen production.
authors.affiliation: Department of Pharmacology & Chemical Biology, University of Pittsburgh and University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA. las22@pitt.edu
authors.forename: Laura P
authors.initials: LP
authors.lastname: Stabile
authors.forename: Mary E
authors.initials: ME
authors.lastname: Rothstein
authors.forename: Diana E
authors.initials: DE
authors.lastname: Cunningham
authors.forename: Stephanie R
authors.initials: SR
authors.lastname: Land
authors.forename: Sanja
authors.initials: S
authors.lastname: Dacic
authors.forename: Phouthone
authors.initials: P
authors.lastname: Keohavong
authors.forename: Jill M
authors.initials: JM
authors.lastname: Siegfried
mesh_terms: D000077384:Anastrozole; D000818:Animals; D047072:Aromatase Inhibitors / Q000627:therapeutic use; D002273:Carcinogens / Q000633:toxicity*; D049109:Cell Proliferation / Q000187:drug effects; D004958:Estradiol / Q000031:analogs & derivatives / Q000627:therapeutic use; D020847:Estrogen Receptor Modulators / Q000627:therapeutic use*; D005260:Female; D000077267:Fulvestrant; D007124:Immunoenzyme Techniques; D008175:Lung Neoplasms / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D051379:Mice; D008807:Mice, Inbred BALB C; D009570:Nitriles / Q000627:therapeutic use; D009602:Nitrosamines / Q000633:toxicity*; D011960:Receptors, Estrogen / Q000378:metabolism; D014026:Nicotiana / Q000633:toxicity*; D014230:Triazoles / Q000627:therapeutic use
chemical_list: D047072:Aromatase Inhibitors; D002273:Carcinogens; D020847:Estrogen Receptor Modulators; D009570:Nitriles; D009602:Nitrosamines; D011960:Receptors, Estrogen; D014230:Triazoles; D000077267:Fulvestrant; D000077384:Anastrozole; D004958:Estradiol; C016583:4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone